IRIS
MASSIMINO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.979
EU - Europa 1.809
AS - Asia 969
SA - Sud America 306
AF - Africa 251
OC - Oceania 2
Totale 6.316
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.891
IT - Italia 749
SG - Singapore 562
IE - Irlanda 336
BR - Brasile 286
CN - Cina 284
UA - Ucraina 223
CI - Costa d'Avorio 155
DE - Germania 125
BE - Belgio 90
CA - Canada 86
NL - Olanda 75
SN - Senegal 73
RU - Federazione Russa 68
VN - Vietnam 39
GB - Regno Unito 28
SE - Svezia 24
IN - India 16
FI - Finlandia 14
CZ - Repubblica Ceca 13
FR - Francia 13
UZ - Uzbekistan 13
CH - Svizzera 12
NG - Nigeria 12
GR - Grecia 11
TR - Turchia 10
AR - Argentina 8
PL - Polonia 7
IR - Iran 6
AT - Austria 5
BD - Bangladesh 5
IQ - Iraq 5
JP - Giappone 5
BG - Bulgaria 4
EC - Ecuador 4
HK - Hong Kong 4
MA - Marocco 4
NO - Norvegia 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
ES - Italia 3
LB - Libano 3
AU - Australia 2
AZ - Azerbaigian 2
EG - Egitto 2
IL - Israele 2
KR - Corea 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
VE - Venezuela 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CO - Colombia 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
MX - Messico 1
NI - Nicaragua 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UY - Uruguay 1
Totale 6.316
Salva come PNG Salva come JPEG
Città #
Santa Clara 720
Chandler 443
Dublin 336
Singapore 330
Chicago 279
Jacksonville 222
Catania 191
Abidjan 155
Boardman 126
Cambridge 94
Lawrence 92
Andover 88
Ashburn 86
Nanjing 82
Dakar 73
Grafing 65
Toronto 60
Civitanova Marche 59
Rotterdam 52
Wingene 50
Des Moines 49
San Mateo 44
Wilmington 44
Palermo 33
Dong Ket 27
Munich 25
Brussels 24
Milan 24
Ottawa 20
São Paulo 20
Shenyang 18
Hebei 17
Nanchang 17
Jiaxing 16
Rome 16
Falls Church 15
Los Angeles 15
Saint Petersburg 15
Bari 14
Changsha 14
Council Bluffs 14
Aci Catena 13
Seattle 13
Abuja 12
Bremen 12
Hanoi 12
Santa Venerina 12
Brno 11
Messina 11
Nijmegen 11
Beijing 10
Belo Horizonte 10
Helsinki 9
Izegem 9
Pune 9
Tianjin 9
Brasília 8
Redmond 8
Rio de Janeiro 8
San Giovanni la Punta 8
Curitiba 7
Mascalucia 7
Acireale 6
Bernareggio 6
Leawood 6
Moscow 6
Paternò 6
Portland 6
Reggio Emilia 6
Washington 6
Fantina 5
Giardini-Naxos 5
Guangzhou 5
Hanover 5
Lappeenranta 5
Mazzarino 5
Milazzo 5
Norwalk 5
Tokyo 5
Ardabil 4
Augusta 4
Comiso 4
Edinburgh 4
Florence 4
Grammichele 4
Hangzhou 4
Houston 4
Jinan 4
Knoxville 4
Liberty Lake 4
Manaus 4
Motta Sant'Anastasia 4
Siracusa 4
Tashkent 4
Temse 4
Trecastagni 4
Zafferana Etnea 4
Zhengzhou 4
Ann Arbor 3
Arcugnano 3
Totale 4.468
Salva come PNG Salva come JPEG
Nome #
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 184
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 151
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 110
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 106
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 105
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 103
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 96
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 96
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 91
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 91
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 84
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 82
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 82
Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series 81
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 81
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 81
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 80
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 79
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 78
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 78
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 78
Uncommon long-term survival in a patient with chronic myeloid leukemia 77
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 77
New insights in thyroid cancer and p53 family proteins 77
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 77
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 76
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 76
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 75
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 75
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 75
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 74
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 74
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 74
A novel and selective sigma-1/2 receptor ligand (PO680C): Binding properties and expression of tissue transglutaminase 74
Comparative proteomic analysis of insulin receptor isoform A and B signaling 73
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 72
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 71
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 71
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 71
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 70
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 69
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 69
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 68
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 68
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 67
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 67
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series 66
A novel and selective σ1/2 receptor ligand (PO680C): binding properties and expression of tissue transglutaminase 65
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 65
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 63
Opportunities and challenges of liquid biopsy in thyroid cancer 62
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 62
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 61
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 60
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 60
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 59
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 59
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 58
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 57
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 57
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy 56
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 56
UNFAVOURABLE OUTCOME OF CML PATIENTS CARRYING COMPLEX VARIANT CHROMOSOMAL TRANSLOCATIONS TREATED WITH TYROSINE KINASE INHIBITORS 55
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 55
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 54
Ruolo delle IAPs e di Smac/DIABLO nella resistenza ai farmaci antiblastici di cellule di carcinoma indifferenziato della tiroide 53
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 52
High BCR-ABL expression levels at diagnosis may predict unfavorable CML responses to Imatinib therapy 52
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 52
Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report 51
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 50
HIGH BCR-ABL EXPRESSION LEVELS AT DIAGNOSIS MAY PREDICT UNFAVOURABLE CML RESPONSES TO IMATINIB THERAPY 50
Experimental and Computational Characterization of Amino Acidic Residues in the BCR-ABL kinase domain contributing to TKI resistance in patients with Chronic Myeloid Leukemia 49
EFFICACY OF IMATINIB MESYLATE ON CHRONIC PHASE CML PATIENTS ACCRUED IN THE SCREEN MULTICENTER STUDY: INTERIM REPORT ON THE FIRST 193 CASES 49
SYNTHESIS OF BNIT AN ISOTHIOCYANATE DERIVATIVE OF N-BENZYL-NORMETAZOCINE AS ACYLANT AGENT FOR σ1 RECEPTOR 49
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 48
L’attività tirosin-chinasica di BCR/Abl modula l’espressione di IRF-5 48
Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines 47
HIGH BCR-ABL LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH UNFAVORABLE RESPONS- ES TO IMATINIB 47
THE SCREEN PROJECT: A CML DATA REGISTRY IN SICILY AND CALABRIA 46
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 46
Computational and biological characterization of nuclear import/export signals of the human BCR protein 45
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 45
High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib 44
IRF5 promotes the proliferation of human thyroid cancer cells. 44
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 43
Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor 40
RAPID RESPONSE TO DASATINIB IN A CML BLAST CRISIS PATIENT THAT SUBSEQUENTLY DEVELOPED SEQUENTIAL BCR-ABL MUTATIONS CAUSING MULTI-DRUG RESISTANCE: A CASE REPORT 39
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 39
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 38
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 37
Molecular dynamics simulations reveal the role of five BCR-ABL kinase domain critical residues in TKIS binding 37
SINTESI E VALUTAZIONE FARMACOLOGICA DI DERIVATI METIL 2-[(4-BENZILPIPERIDIN-1-IL)METIL]-1-FENIL-CICLOPROPANCARBOSSILATO COME LIGANDI SIGMA AD ALTA AFFINITÀ 36
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib 34
TOWARDS A NEED IN OPTIMIZING CML MANAGEMENT IN SUBOPTIMAL RESPONDERS: DATA FROM THE SCREEN REGISTRY 33
Computational and Experimental Characterization of Critical Amino Acid Residues in the BCR-ABL Kinase Domain Explaining Imatinib Resistance in Patients with Chronic Myeloid Leukemia 32
HIGH DOSE IMATINIB TO ACHIEVE MOLECULAR RESPONSES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN LATE CHRONIC PHASE AND COMPLETE CYTOGENETIC RESPONSE: IS IT WORTHWHILE? 32
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 30
HIGH BCR-ABL EXPRESSION LEVELS AT DIAGNOSIS MAY PREDICT UNFAVOURABLE CML RESPONSES TO IMATINIB THERAPY 29
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 24
Totale 6.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.432
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.432
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202096 0 0 0 0 0 0 0 0 0 0 45 51
2020/2021545 19 38 49 11 130 16 51 3 108 4 68 48
2021/2022693 55 98 15 9 113 13 104 27 53 14 35 157
2022/20231.376 107 102 43 153 91 215 19 264 289 11 50 32
2023/2024771 57 107 30 37 32 184 11 44 7 35 137 90
2024/20252.509 115 447 117 175 591 397 191 81 188 206 1 0
Totale 6.511